Supernus Pharmaceuticals, Inc. (SUPN) announced that its stockholders have voted to approve the previously disclosed merger agreement with Indivior Pharmaceuticals Inc. The approval was granted during a special meeting of stockholders held on October 15, 2026. This vote is a significant step toward the completion of the transaction, which will result in Supernus becoming a wholly-owned subsidiary of Indivior.
Key Details
- Merger Proposal: The proposal to adopt the Merger Agreement was approved with 48,249,532 votes for, 235,601 against, and 67,004 abstentions.
- Executive Compensation: A separate, non-binding proposal to approve compensation for named executive officers in connection with the merger also passed, with 32,688,410 votes for and 15,847,350 against.
- Record Date: As of the September 4, 2026 record date, there were 58,224,143 shares of common stock outstanding and entitled to vote.